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BACKGROUND: Molecular profiling has identified at least four subtypes of invasive breast carcinoma, which exhibit distinct clinical
behaviour. There is good evidence now that DCIS represents the non-obligate precursor to invasive breast cancer and therefore it
should be possible to identify similar molecular subtypes at this stage. In addition to a limited five-marker system to identify molecular
subtypes in invasive breast cancer, it is evident that other biological molecules may identify distinct tumour subsets, though this has
not been formally evaluated in DCIS.
METHODS: Tissue microarrays were constructed for 188 cases of DCIS. Immunohistochemistry was performed to examine the
expression patterns of oestrogen receptor (ER), progesterone receptor (PR), Her2, EGFR, cytokeratin (CK) 5/6, CK14, CK17, CK18,
b4-integrin, b6-integrin, p53, SMA, maspin, Bcl-2, topoisomerase IIa and P-cadherin. Hierarchical clustering analysis was undertaken to
identify any natural groupings, and the findings were validated in an independent sample series.
RESULTS: Each of the intrinsic molecular subtypes described for invasive breast cancer can be identified in DCIS, though there are
differences in the relative frequency of subgroups, in particular, the triple negative and basal-like phenotype is very uncommon in
DCIS. Hierarchical cluster analysis identified three main subtypes of DCIS determined largely by ER, PR, Her2 and Bcl-2, and this
classification is related to conventional prognostic indicators. These subtypes were confirmed in an analysis on independent series of
DCIS cases.
CONCLUSION: This study indicates that DCIS may be classified in a similar manner to invasive breast cancer, and determining the
relative frequency of different subtypes in DCIS and invasive disease may shed light on factors determining disease progression. It also
demonstrates a role for Bcl-2 in classifying DCIS, which has recently been identified in invasive breast cancer.
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DCIS is the non-obligate precursor of invasive breast cancer
and accounts for an increasing proportion of breast cancer,
particularly in the screening setting. In the UK NHS Breast
Screening Programme for 2008–2009, 14166 new breast cancers
were detected, of which 20% were DCIS (NHSBP 2008–2009;
http://www.ic.nhs.uk/webfiles/publications/breast_screening/Breast_
Screening_Programme_Report_2008_09.pdf). Despite the incre-
ased frequency of detection, the biology of DCIS is poorly
understood. A number of histopathological classifications have
been proposed to distinguish between different types of DCIS
(reviewed in the study by Jones, 2006). The classification system
most widely used is based on nuclear morphology, yielding three
categories of high-, intermediate- and low-nuclear grades. This
classification has some prognostic power with greater risk of
recurrence being associated with high-nuclear grade; however,
poor reproducibility limits the clinical value of this system.
In invasive breast cancer, recent advances have led to an
emerging molecular classification based more on the biological
characteristics of the tumour rather than limited to morphological
analysis. The seminal work of Perou et al (2000) identified novel
subtypes of invasive breast cancer based on an intrinsic gene
signature established by cDNA microarray analysis. These
subgroups have been refined by Sorlie et al (2001) and shown to
have prognostic significance. Many studies have aimed to identify
an immunohistochemical profile that can act as a surrogate for
gene array analysis (Makretsov et al, 2004; Nielsen et al, 2004;
Matos et al, 2005), and it appears that a five-marker panel of
oestrogen receptor (ER), progesterone receptor (PR), Her2, CK5/6
and EGFR shows promise in its ability to categorise invasive
cancers to their molecular subtype (Cheang et al, 2008).
Much less attention has focussed on dissecting the biological
subtypes of DCIS, and there are discrepancies in the results of
those studies that exist. Thus, whereas several studies report the
existence of a basal subtype of DCIS (Livasy et al, 2007; Paredes
et al, 2007; Tamimi et al, 2008), one gene array study found no
good evidence of this category of DCIS (Hannemann et al, 2006).
There are also discrepancies in the relative frequency of subtypes
between the in situ and invasive disease.
Whereas it has been recognised for some time that there is
a higher frequency of Her2-positive DCIS compared with
Her2-positive invasive breast cancer (Park et al, 2006), there are
Received 2 June 2010; revised 26 October 2010; accepted 4 November
2010; published online 7 December 2010
*Correspondence: Dr SE Clark or Professor JL Jones;
E-mail: sarahclark74@hotmail.com or l.j.jones@qmul.ac.uk
British Journal of Cancer (2011) 104, 120–127
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sseveral reports suggesting that, if a basal category of DCIS exists, it
is less frequent than basal type invasive carcinoma, though others
suggest a very similar frequency (Livasy et al, 2007; Meijnen et al,
2008; Tamimi et al, 2008). It is important to establish these
relationships as they might help to explain the biological factors
determining progression of DCIS to invasive disease.
Although a five-marker panel has been identified to categorise
breast cancer (Cheang et al, 2008), the biological determinants
underlying the different clinical behaviour between the molecular
subtypes is clearly more complex than implied by such a restricted
biomarker panel. In support of this, a number of studies have
identified further biologically relevant markers that associate
either with a particular subtype or reveal heterogeneity within a
subtype. Thus, P-cadherin has been shown to significantly
associate with the basal subtype, whereas b4-integrin is expressed
by a subset of basal tumours (Paredes et al, 2007; Lu et al, 2008).
Certain markers have been shown to have prognostic or predictive
importance in invasive breast cancer (Umekita et al, 2002; Fritz
et al, 2005; Malamou-Mitsi et al, 2006; Rolland et al, 2007), but
only infrequently have these been applied to DCIS (Shpitz et al,
2000), and a more extensive analysis of the relationship between
these biomarkers and their ability to define different subgroups of
DCIS of potential clinical relevance is lacking.
This study therefore aimed to analyse the expression profile of
16 biomarkers, shown to be biologically relevant in invasive breast
cancer, in a series of 188 cases of pure DCIS. Hierarchical
clustering analysis was performed with the aim of identifying
molecular subtypes of DCIS and how these relate to recognised
subtypes of invasive breast cancer. The analysis was validated
on an independent series of DCIS samples. Follow-up data were
collected for each case to investigate the relationship between DCIS
expression profile and outcome.
PATIENTS AND METHODS
Patient selection and tissue samples
For the test series, all patients treated for DCIS without associated
invasive carcinoma at St Bartholomew’s Hospital, London, UK
between 1994 and 2007 were identified. Patients with DCIS associated
with LCIS and Paget’s disease of the nipple were included in this
study. Tumours involving areas of microinvasion were excluded. For
the validation series, a further 75 cases of DCIS were identified,
diagnosed since 2007. Formalin-fixed paraffin-embedded tissue
blocks were retrieved for each patient and used to construct a tissue
microarray (TMA; Beecher MTA1 machine (Beecher Instruments
Inc., Silver Springs, MD, USA); Alphelys TMA designer, Alphelys,
Plaisir, France). Appropriate areas of DCIS were identified by a
consultant histopathologist (JLJ) and three 1mm cores of DCIS
were taken from each case. Cores of normal breast tissue were also
included in the array as controls. From the arrays, 4mm sections
were cut and mounted on negatively charged glass slides. Follow-up
data and information on treatment, age at diagnosis, histological
grade and extent of disease were collected for all patients using the
medical and nursing notes and electronic patient record system.
Estrogen receptor testing was not routinely performed on all cases
from earlier years in the study, but for those that had undergone
testing the ER status reported on a full section by the St
Bartholomew’s histopathologist was recorded in order to compare
with the scores from the TMAs. The study was granted NHS
Research Ethics Committee approval (COREC No. 06/Q0403/182).
Immunohistochemistry
S e c t i o n sw e r ed e w a x e di nx y l e n ef o r5 m i na n dr e h y d r a t e dt h r o u g h
graded alcohols to distilled water. Optimal antigen retrieval
procedure and dilutions applied for each antibody are summarised
in Supplementary Table 1. Antibodies were used to detect ER
(Novocastra, Milton Keynes, UK, NCL-L-ER6F11), PR (Novocastra,
NCL-L-PGR 1A6), Her2 (Novocastra, NCL-CBe-356 clone 10A7),
EGFR (Dako, Cambridgeshire, UK, K1492), CK 5/6 (Dako, D5/16B4),
CK14 (Serotec, Kidlington, UK, LL002), CK17 (Sigma, Sigma-Aldrich,
Dorset, UK, CK-E3), CK18 (Serotec, CY90), SMA (Dako, 1A4), p53
(Novocastra, NCL-p53-DO7), topoisomerase IIa (Novocastra, 3F6),
Bcl-2 (Abcam, Cambridge, UK, 100/D5), maspin (Pharmingen,
Oxford, UK, G167-70), b4-integrin (Chemicon, Watford, UK, W439-
9B), b6-integrin (Gift from J Marshall 62G2) and P-cadherin (BD
Transduction Labs, 56, Oxford, UK). The primary antibodies were
diluted in a blocking solution containing the appropriate animal
serum and 0.1% bovine serum albumin. Slides were incubated in the
primary antibody for 2h at room temperature or overnight at 41C.
After washing the slides, the appropriate secondary antibody was
applied and slides were incubated for 30min at room temperature.
Further, they were washed, and then Streptavidin ABC complex (Dako
K0377) was prepared according to manufacturer’s instructions and
added to the slides for 30min. Antibody was detected with
diaminobenzidine tetrahydrochloride substrate buffer (Vector SK-
4100, Vector Labs Inc., Burlingame, CA, USA) prepared according to
manufacturers’ instructions. After 5min incubation, sections were
washed, counterstained with haematoxylin, dehydrated and mounted.
Each run included appropriate positive and negative controls.
Interpretation of staining
The staining patterns were scored according to the percentage of
DCIS tumour cells staining positive for each antibody. The same
scoring system was used for all markers to allow direct comparison
between the markers. Samples were either scored as positive when
470% of cells expressed the marker, heterogeneous when 10–70%
of cells expressed the marker, occasional when a few individual
cells expressed the marker or negative when no staining was seen.
For analysis, staining of 410% was considered as positive. Only
appropriately located staining for a given marker was scored, that
is, nuclear for ER and PR, membrane staining for Her2.
Two independent researchers performed the scoring (SEC and
JLJ). All samples were coded before scoring, therefore researchers
were blinded to outcome. Comparison was made between the two
observers results and, when in conflict, the core was reviewed
together and a consensus score agreed.
Statistical analysis
Tetrachoric paired correlation Tetrachoric correlation was used
to measure the degree of association between pairs of markers. An
absolute value for the correlation coefficient between 0.1 and 0.3
was taken to indicate weak correlation, between 0.3 and 0.5 to
indicate moderate correlation and between 0.5 and 1 to indicate
strong correlation.
Cluster analysis Natural groupings in the data were identified
using unsupervised hierarchical agglomerative cluster analysis
with average linkage on the 16 potential biomarkers. Biomarkers
were dichotomised (1¼positive, 0¼negative) to create binary
variables with positive and heterogeneous staining being coded as
positive and occasional or negative being coded as negative.
Simple matching was used to measure the distances between the
clusters. The optimal number of clusters for any given set of
biomarkers was determined with reference to both the Calinski,
(1973) and Duda (1973) stopping rules.
Fisher’s exact test The Fisher’s exact statistic (used instead of a w
2
when the expected value in any cell was o5) was used to test for an
association between group (as determined by the cluster analysis)
and histological grade.
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Patients and tumour characteristics
In the test series, a total of 248 women were diagnosed with pure
DCIS at St Bartholomew’s Hospital between 1994 and 2007. These
were all newly diagnosed either through the screening programme
or as symptomatic cases. Tissue samples were available for 188 of
these and were used to construct the tissue microarrays. Those
samples not available were either missing from the file, or the
tissue paraffin blocks had been damaged during storage. In two
cases, the patient had only undergone a core biopsy but no
definitive treatment. The tumour characteristics and treatment
of these 188 women are shown in Table 1. The average age at
diagnosis was 56 (range 25–85) years. Breast conservation was the
most frequently used primary surgical treatment (59.6%) and was
combined with a sentinel node procedure in only 10% of these
cases. Mastectomy (with or without sentinel lymph node biopsy or
axillary clearance) was performed in 34% of cases.
The average lesion size was 25mm (range 4–155mm), and
73.9% of the tumours were high grade (HG), 11.2% intermediate
grade (IG) and 10.6% low grade (LG). Tumour grade was not
known in 1.6% of cases. Where the tumour was of mixed
histological grade, the highest was used to define the case. Three
of the DCIS cases had occurred in a radial scar and one in a
fibroadenoma, three were associated with Paget’s disease of the
nipple and two contained areas of LCIS. Adjuvant treatment was
mostly endocrine therapy (42%). In all, 22 women underwent
radiotherapy either in combination with endocrine therapy or
alone. Details of adjuvant treatment were not available for 20
women.
Follow-up data were available for 172 of the cases. The median
length of follow-up was 3.6 years (range 0–10). There were five
recurrences; three of DCIS and two of invasive breast cancer,
giving a recurrence rate of 2.7%. The median time to recurrence
was 2 years (range 1–7 years).
The average size of the missing samples was 14.75mm (range
1–50mm), which was statistically significantly smaller than that
used in the TMAs (P¼0.04); however, there were no differences in
distribution of grades between the missing cores and those used on
the TMAs. Of the missing cases, 63.3% of the tumours were HG,
13.3% were IG and 11.7% were LG. Data were missing on the size
of the tumours in 32 of the 60 cases and on the grade in 7 of the 60
cases (Table 1).
For the validation series, a further 75 cases of DCIS were
analysed. The clinicopathological features of this series showed no
significant difference to the test series (data not shown). Follow-up
in these patients is limited, therefore, relationship to outcome was
not assessed.
Comparison of TMA samples and whole sections
To evaluate how representative the TMA samples were of the
whole-tissue section, the grade of DCIS made on TMA was
compared with that on whole sections in 187 cases (according to
tissue availability), and ER status was compared in 99 cases.
For grade, the same grade was allocated in 168 cases, giving
a concordance rate of 89.8%. Those that differed did so by one
grade, with no consistent pattern. For ER status, the score on the
whole-tissue section differed from the TMA score in only 10 cases,
giving a concordance rate of 94%.
Expression of biomarkers
The distribution of staining for each marker is shown in Figure 1.
Several markers displayed significant heterogeneity within cases,
most notably maspin, p53, EGFR and topoisomerase IIa. However,
for the purpose of analysis, any case exhibiting 410% tumour cells
staining was designated as positive. Results from at least one of the
three DCIS cores were interpretable for between 108 and 178 cases
for different markers. Of the interpretable staining, 69.7% cases
were positive for ER and 52.1% were positive for PR, and there was
a strong correlation between these two markers (Table 2). Her2
was positive in 25.3% of cases and showed an inverse correlation
with ER and PR status. Basal CK5/6 and CK14 were expressed in
11.9% and 11.4%, respectively, and were strongly correlated with
each other. The highest level of tissue loss was seen with EGFR but
data were available on 108 cases, and 27.8% of these showed
positive staining.
Using this limited panel of markers, it is possible to allocate
samples to the intrinsic molecular subtypes defined by Perou et al
Table 1 Patient, tumour and treatment characteristics
TMA cases
(N¼188)
Missing cases
(N¼60)
Characteristic Number % Number %
Mean age, years (range) 56 (25–85) 66 (43–95)
Laterality
Left breast 95 50.5 22 44
Right breast 89 47.4 28 56
Unknown 4 2.1 9 18
Primary surgical treatment
Mastectomy alone 14 7.4 3 5.1
+Axillary node clearance 8 4.3 0 0
+Sentinel node procedure 42 22.3 1 1.7
Breast-conserving surgery 100 53.2 29 49.2
+Axillary node clearance 0 0 1 1.7
+Sentinel node procedure 12 6.4 12 20.3
Excision biopsy 9 4.8 3 5.1
Unknown 3 1.6 11 16.9
Secondary surgical treatment
Mastectomy 35 18.6 10 16.9
Breast-conserving surgery 25 13.2 11 18.6
Third surgical treatment
Mastectomy 8 4 2 3.4
Breast-conserving surgery 2 1 0 0
Lesion size
1–10mm 19 10.1 11 18.3
11–20mm 35 18.6 7 11.7
21–30mm 17 9.0 2 3.3
31–40mm 11 5.9 0 0
41–50mm 8 4.3 2 3.3
450mm 7 4.3 0 0
Multicentric/multifocal 17 9.0 5 8.3
Extensive 10 5.3 1 1.8
Not stated 63 33.5 32 53.3
Grade
Low 20 10.6 7 11.7
Intermediate 25 13.3 8 13.3
High 140 74.5 38 63.3
Unknown 3 1.6 7 11.7
Adjuvant therapy
Radiotherapy
Yes 22 11.7 8 13.3
No 145 77.1 43 71.7
Unknown 21 11.2 9 15.0
Endocrine
Yes 80 42.6 22 36.7
No 88 46.8 29 48.3
Unknown 20 10.6 9 15.0
Abbreviation: TMA¼tissue microarray.
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s(2000) and by these surrogate immunohistochemical markers in
several studies (Carey et al, 2006; Paredes et al, 2007). Thus, the
DCIS samples were categorised as luminal A (ERþ/PRþ/Her ),
luminal B (ERþPRþ or PR /Her 2þ), Her 2 (ER /PR /
Her2þ) and triple negative (TN; ER /PR /Her2 ). Within the
TNs, we identified a basal-like sub-group (ER /PR /Her2 /CK5/6
and/or EGFRþ). We found that 38.3% were luminal A, 6.9% were
luminal B, 14.9% were Her2 overexpressing and 7.5% were TN.
Basal-like tumours comprised 57.1% of TN tumours and 4.2% of
the total number of cases. A total of 32.5% was not classifiable
owing to lack of information on one or more markers.
A wider analysis of basal and luminal cytoskeletal proteins
showed expression of basal CK17 in 25.9% of cases, and the
myoepithelial-associated SMA in 8.3% of cases, whereas the
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Figure 1 Graphical representation of staining patterns.
Table 2 Pairwise tetrachoric correlation coefficients indicating the strength and direction of associations between staining positive for one biomarker and
staining positive for another
ER PR Her2 CK56 CK14 CK17 CK18 TopIIa b4 b6 SMA Maspin Bcl-2 EGFR P-cad-herin p53
ER 1.00
PR 0.81 1.00
Her2  0.71  0.62 1.00
CK56  0.03 0.36 0.00 1.00
CK14  0.42  0.26 0.14 0.81 1.00
CK17  0.02 0.02 0.04 0.13 0.30 1.00
CK18 0.42 0.02 1.00 1.00  0.21  0.06 1.00
TopIIa  0.11  0.41 0.29  0.17 0.09  0.18  0.09 1.00
b4  0.00 0.01 0.34 0.53 0.61 0.07 0.09 0.29 1.00
b6  0.52  0.60 0.47  0.15  0.04 0.23 1.00 0.11  0.11 1.00
SMA 0.03  0.22 0.12 0.71 0.78 0.05 1.00  1.00  0.07  1.00 1.00
Maspin  0.04  0.16 0.45 0.05 0.38 0.32 0.36 0.19  0.19 0.45 1.00 1.00
Bcl-2 0.86 0.60  0.67 0.14  0.01  0.09 0.68  0.14  0.09  0.45  0.01 0.05 1.00
EGFR  0.08  0.34  0.30  1.00  0.13 0.08  0.17 0.39 0.02 0.04  1.00 0.01  0.28 1.00
P-cadherin  0.78  0.77 0.66  0.18 0.47 0.18  0.47 0.47 0.27 0.11 0.19 0.04  0.73  0.20 1.00
p53  0.34  0.47 0.50  0.07  0.13 0.33 0.13 0.37 0.05 0.42  1.00 0.10  0.44 0.09 0.21 1.00
Notes: (1) A positive value for correlation indicates that being positive for one marker is associated with being positive for the other, and vice versa. (2) A negative value for
correlation indicates that being positive for one marker is associated with being negative for the other, and vice versa. (3) An absolute value for the correlation coefficient of
between 0.1 and 0.3 indicates weak correlation, between 0.3 and 0.5 indicates moderate correlation and between 0.5 and 1 indicates strong correlation.
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previously associated with a basal-like phenotype exhibited
varying levels of expression: p53 staining was evident in 40.4%
of samples whereas P-cadherin was positive in 20% of cases, and
the myoepithelial-associated b4-integrin was expressed in 29.9%
cases, with b6-integrin staining in only 9.8% of samples.
The paired correlations identified between the markers is
summarised in Table 2. The basal CKs were inversely correlated
with luminal CK and also with ER. A positive association was
also demonstrated between b4-integrin and basal CK14 and
between P-cadherin and p-53 positivity.
Approximately 57.9% of cases that were interpretable showed
staining for topoisomerase IIa and this was inversely correlated
with ER and PR, while maspin was expressed in 58.5% cases and
showed a moderate association with both basal CK14 and with
Her2 positivity (Table 2). The anti-apoptotic Bcl-2 protein was
expressed in 69.1% of cases and was strongly positively associated
with ER and PR, and negatively associated with basal CKs, Her2,
p53, b4-integrin and P-cadherin.
Expression of ER, PR, CK14 and Bcl-2 was associated with LG,
whereas Her2, p53 and P-cadherin expression was associated with
HG. No association was found between other markers and grade.
Hierarchical cluster analysis
The first cluster analysis, using all 16 markers, did not identify any
distinct subgroups. This may, in part, be due to missing data for
individual markers on different cases. A second cluster analysis
was therefore performed on a reduced set of markers (those that
were at least 80% complete and thought to have the most biological
relevance), which were ER, PR, Her2, CK5/6, CK14, topoisomerase
IIa, b4-integrin, b6-integrin, Bcl-2, maspin and p53. This led to the
identification of two distinct subgroups.
Four markers were the key determinants: ER, PR, Her2 and
Bcl-2. Individuals in subgroup 1 were predominantly ER ,P R  ,
Her2þ and Bcl-2 , and individuals in subgroup 2 were
predominantly ERþ,P R þ, Her2  and Bcl-2þ. To maximise
the number of individuals included, a third cluster analysis was
performed using only the four key markers. This increased the
sample size from 128 to 150 and led to four distinct groupings. The
associated dendrogram is shown in Figure 2.
Of the 150 cases, 27 (18.0%) fell into group 1 (largely ER ,P R  ,
Her2þ and Bcl-2 ), 19 (12.7%) into group 2 (largely ER ,P R  ,
Her2  and Bcl-2 ), 9 (6%) into group 3 (largely ERþ,P R þ,
Her2  and Bcl-2þ) and 7 (4.7%) into group 4 (largely ERþ,
PRþ, Her2  and Bcl-2 ). There was a statistically significant
association between grade and group (P¼0.003, Fisher’s exact),
with group 1 tumours being almost exclusively HG (96%), 84% of
group 2 tumours being HG and 63% of group 3 tumours being HG
(Table 3). The Cuzick test (Cuzick, 1985) for trend across the
groups 1–3 was highly significant (Po0.001).
Group 1, therefore, roughly corresponds to the Her2 subtype,
group 2 to the TN subtype and both groups 3 and 4 to the
luminal A subtype. Within groups 3 and 4, there are a small
number of cases that are both ERþ and Her2þ and therefore
correspond to the luminal B subtype. In group 1, 10% of tumours
were ER positive, in group 2, 42% were ER positive and in group 3,
94% were ER positive. Consequently, it may be that the observed
association between group and grade reflects only the known
association between ER status and grade. Therefore, to assess the
independent prognostic influence of ER, PR, Her2 and Bcl-2 and to
investigate whether the relationship between grade and Her2 status
is consistent across all levels (i.e., a tumour that is Her2 positive is
most likely to be HG, less likely to be of IG and least likely to be of
LG), we performed an ordered logistic regression analysis with
grade (LG, IG and HG) as the three-level dependent variable and
ER, PR, Her2 and Bcl-2 as binary (positive/negative) explanatory
variables. Her2 and PR statuses were significant in the multivariate
model (P¼0.03 and P¼0.02, respectively), suggesting that both
Her2 and PR statuses are independent measures of tumour
aggressiveness, and that the groups found do provide additional
information to ER status alone. Putting all the biomarkers thought
to be of biological relevance into the ordered logistic regression led
to similar findings (Table 4).
As tumour size is also a measure of disease aggressiveness,
we repeated the analysis with size group (1¼0–10mm, 2¼11–
15mm, 3¼16–30mm, 4¼X31 mm) as the dependent variable
but there was no significant association with any of the
biomarkers.
To examine the robustness of this clustering, a validation set of
75 cases of DCIS was stained for ER, PR, Her2 and Bcl-2, scored in
a similar manner and subjected to hierarchical cluster analysis.
This identified the same three main groups: ER ,P R  , Her2þ
and Bcl-2  (n¼20); ER ,P R  , Her2  and Bcl-2  (n¼9); ERþ,
PRþ, Her2  and Bcl-2þ (n¼43), confirming the robustness of
the classification.
DISCUSSION
Molecular profiling by gene array and its translation into surrogate
immunohistochemistry profiles is likely to have a major impact on
breast cancer classification and management, and it is important
that similar approaches are taken to advance the understanding of
DCIS. This study has analysed a large series of pure DCIS samples
constructed into TMAs for their expression profile of 16
biomarkers, many of which previously have been shown to
distinguish between different subtypes of invasive breast cancer.
We demonstrate that each of the intrinsic subtypes identified in
invasive breast cancer is also recognised in DCIS, though there are
differences in the relative frequencies of the groups in the two
stages of disease.
There are practical challenges in using TMAs for the analysis of
DCIS, with a higher ‘loss rate’ than is seen with invasive
carcinoma, a limitation also reported by others (Tamimi et al,
2008). Furthermore, DCIS has been shown to be heterogeneous in
nature and grade can vary within a section (Lennington et al, 1994;
Allred et al, 2008). Expression rates of some biological markers
have also been shown to vary within whole sections (Allred et al,
2008), which indicates that cores used in TMA studies may not be
representative of the whole tumour. To overcome this sampling
bias, three cores of tissue were analysed from each tumour, an
approach validated by other groups studying invasive breast
cancers (Zhang et al, 2003; Selvarajan et al, 2006; Yang et al, 2006;
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sDrev et al, 2008). A comparison of DCIS grade and ER status was
made between TMAs and whole-tumour sections, and this showed
B90% concordance between the two sample types for both
parameters, suggesting that three cores are reasonably representa-
tive of whole sections.
The same scoring system was used for all markers to allow direct
comparison between markers. Samples were either scored as
positive when 470% of cells expressed the marker, heterogeneous
when 10–70% of cells expressed the marker, occasional when a few
individual cells expressed the marker or negative when no staining
was seen. In invasive breast cancers, the Quick score (Leake et al,
2000) is used to score ER expression, and variable systems have
been used to score other biomarkers, including a cutoff of 410%
as positive (Rakha et al, 2007). There is currently no consensus on
the scoring of biomarkers in DCIS, though a similar percentage
cutoff for ER is used in some clinical trials (Cuzick, 2008). Thus,
the scoring system is in keeping with other published studies,
allowing some level of comparison.
According to the criteria of Carey et al (2006), this study showed
a frequency of 38.3% for luminal A, 6.9% luminal B, 14.9% Her2,
7.5% TN and 4.2% basal-like in this series of DCIS cases. In
invasive breast cancer, frequencies between 58–75% for luminal A,
11–16% for luminal B, 3–6% for Her2 and 11–20% for TN/basal
have been reported (Carey et al, 2006; Kurebayashi et al, 2007;
Rakha et al, 2007; Kwan et al, 2009). Thus, in keeping with
previous reports (Park et al, 2006), we show a higher frequency of
Her2-positive DCIS compared with invasive disease, but lower
frequency of TN and basal subtypes.
Meijnen et al (2008) carried out an immunohistochemical study
on 163 cases of pure DCIS analysing 16 markers. Interestingly, they
showed no evidence of CK14 or EGFR expression in their series of
DCIS, with CK5/6 being expressed in only three cases.
In an unsupervised cluster analysis, they identified two major
groups, an ERþ/Bcl-2þ group designated as ‘luminal’, and an
ER /Bcl-2  group designated as non-luminal, in keeping with the
results of this study. The luminal subgroup was further subdivided
into ARþ,A R   and mixed groups, whereas the non-luminal
group was subdivided into Her2þ and Her2  subsets. There was
a significant relationship between grade and distribution between
subsets, with significantly more well-grade and IG DCIS clustering
in the luminal groups compared with non-luminal groups. They
demonstrated that the IG DCIS shared more features with well-
differed than poorly differentiated DCIS and show that the Bcl-2-
positive luminal subgroup may indicate a more favourable group
of lesions. This is in keeping with the unsupervised hierarchical
cluster analysis in the current study, which also separated DCIS
into ER ,P R  , Her2 , Bcl-2  and ERþ,P Rþ, Her2 , Bcl-2þ
subtypes, with a further ER , Her2  group. Furthermore, Meijnen
et al also report a low frequency of basal-like/TN DCIS cases,
however they define that phenotype. Thus, CK14 was not detected
in any of their cases, and CK5/6 in only three cases. When using
the TN definition, only eight cases were found to be ER/PR/Her2
negative.
This is in contrast to a study by Livasy et al (2007), who, in an
analysis of 245 pure DCIS cases, identified 8% as basal (defined as
ER , Her2 , EGFRþ and/or CK5/6þ) and a further 6% fell into
the TN category. This frequency of 14% correlates with the
frequency of the basal/TN category in sporadic invasive breast
cancers. These differences may be related to analysis of whole-
tissue sections vs TMAs and reflect the heterogeneity reported in
DCIS, or may reflect a different spectrum of DCIS analysed.
Tamimi et al (2008) also report significant differences between
molecular phenotypes in DCIS and invasive breast cancer. In a
large study comparing the immunoprofile of invasive breast cancer
(n¼2249) and their associated DCIS (n¼272), they showed that
the basal subtype (defined as ER/PR/Her2 negative, positive for
EGFR and for CK5/6) was less frequent in DCIS compared with
invasive cancers (7.7 of 10.9%), and more so when restricted to
Table 3 Comparison of percentage positive cases for each marker with those available in the literature
Published literature
Marker Normal breast DCIS % positive Source
% of cases expressing
marker in this study
ER Low levels of expression 57–88 (Malafa et al, 1990; Chaudhuri et al, 1993; Suo et al, 2001) 60.2
PR Low levels of expression 40–80 (Suo et al, 2001; Bryan et al, 2006) 46.4
Her2 Not expressed 34–67 (Suo et al, 2001; Bryan et al, 2006) 22.4
EGFR Myoepithelial cells 8.2–94 (Suo et al, 2001; Bryan et al, 2006; Dabbs et al, 2006) 17.3
CK5/6 Myoepithelial cells 3.7–24 (Otterbach et al, 2000; Abd El-Rehim et al, 2004a; Bryan et al, 2006) 10.2
CK14 Myoepithelial cells 19.4–24 (Abd El-Rehim et al, 2004a; Bryan et al, 2006) 9.2
CK17 Myoepithelial cells 32 (Abd El-Rehim et al, 2004a; Bryan et al, 2006) 19.4
CK18 Luminal cells 88 (Abd El-Rehim et al, 2004a) 79.1
SMA Myoepithelial cells 43.8 (Rakha et al, 2006) 6.6
p53 Mutation not expressed 10–20 (Done et al, 2001; Ribeiro-Silva et al, 2003; Malamou-Mitsi et al, 2006) 35.2
TopIIa Low levels of expression 6.8 (Shpitz et al, 2000; Fritz et al, 2005) 49.0
Bcl-2 Myoepithelial cells 52–81.8 (Malamou-Mitsi et al, 2006; Park et al, 2006; Rolland et al, 2007) 47.5
Maspin Myoepithelial cells 9.6 (Zou et al, 1994; Umekita et al, 2002) 50.7
b4 Myoepithelial cells 18 (Hanby et al, 1993) 19.9
b6 Not expressed — (Arihiro et al, 2000) 9.2
P-Cad Myoepithelial cells 25–100 (Peralta Soler et al, 1999; Kovacs et al, 2003; Paredes et al, 2007) 12.8
Abbreviation: DCIS¼ductal carcinoma in situ.
Table 4 Odds ratios for grade (low, intermediate, high) from the multivariate ordered logistic regression analysis (n¼148)
Biomarker No. (negative/positive) Odds ratio (univariate) Odds ratio (multivariate) 95% Confidence interval P-value
ER 44/104 0.17 0.88 0.22–3.57 0.86
PR 68/80 0.21 0.34 0.12–0.92 0.03
Bcl-2 47/101 0.22 0.61 0.17–2.22 0.45
Her2 109/39 10.38 12.45 1.55–99.98 0.02
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significantly more frequent in DCIS compared with invasive
disease (13.6 of 5.5%), as previously reported, as was the luminal B
subtype (defined as ERþ/Her2þ), reported as 13.2% frequency in
DCIS compared with 5.2% in invasive cancers.
As a result of the application of different definitions for
subtypes, in particular the basal/TN category, it is difficult to
make direct comparisons between studies; however, Tamimi et al
(2008) and Livasy et al (2007) use the same definition for basal,
and report frequencies in DCIS of 7.7 and 8%, in contrast to the
very low frequency (B1.8%) reported on the basis of CK5/6
staining by Meijnen et al (2008). Hannemann et al (2006) also
found the basal phenotype to be infrequent in DCIS, with only 2 of
39 cases showing expression of CK5/6.
Owing to the relatively low rate of recurrence of DCIS, either as
in situ or invasive disease, there are a few studies that relate
molecular phenotype or biomarker expression of DCIS to the
outcome. In most studies, results are extrapolated from knowledge
of associations with behaviour in invasive breast cancer. Thus, it is
well recognised that the basal/TN subtype is associated with more
aggressive disease in invasive cancers, therefore, it is postulated that
DCIS with a basal phenotype is likely to exhibit more aggressive
behaviour. This is not a foregone conclusion and other factors may
be at play, such as microenvironmental changes, that may be of
more importance in DCIS than established invasive disease.
Few studies have undertaken genomic analysis of DCIS. One of
the largest studies to date is reported by Hannemann et al (2006),
who carried out gene expression microarray analysis of 39 cases
of DCIS. An unsupervised cluster analysis identified two major
subgroups, a predominantly ERþ group and a predominantly
ER– group. Discrimination of a Her2þ subgroup was not as clear,
and they could not identify a significant basal-type group, which
would appear to support the IHC studies, suggesting that this
phenotype is infrequent in DCIS. In an analysis to identify a
gene classifier that could distinguish between LG and HG DCIS,
Bcl-2 was one of the top genes being upregulated in the well-
differentiated samples, again, correlating with the results reported
in the current study. It is also of note that Bcl-2 has recently been
reported as a powerful independent predictor of good prognosis
in a study of 411000 invasive breast carcinomas (Dawson et al,
2010), and this further suggests that the clustering of DCIS into
subgroups defined in part by Bcl-2 may be of functional and
clinical importance.
CONCLUSIONS
The results of this study indicate that it may be possible to classify
DCIS according to its immunohistochemical expression profile,
and that individual markers act independently of ER in associating
with grade. The relative frequency of molecular subtypes in DCIS
vs invasive disease provides some insight into the impact of
molecular subtype on progression. This is important as, if a group
of patients with very low-risk DCIS could be identified, the over-
treatment of women, particularly in the breast-screening setting,
could be reduced, and the associated psychological and physical
harms thereby minimised or avoided.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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